Dhal Ajit Kumar, Panda Chinmaya, Yun Soon-Il, Mahapatra Rajani Kanta
School of Biotechnology, KIIT Deemed to Be University, Bhubaneswar, Odisha 751024 India.
Department of Food Science and Technology, Jeonbuk National University, Jeonju, 54896 Republic of Korea.
J Parasit Dis. 2022 Sep;46(3):923-939. doi: 10.1007/s12639-022-01510-5. Epub 2022 Jun 22.
species has been identified as an important pediatric diarrheal pathogen in resource-limited countries, particularly in very young children (0-24 months). However, the only available drug (nitazoxanide) has limited efficacy and can only be prescribed in a medical setting to children older than one year. Many drug development projects have started to investigate new therapeutic avenues. 's unique biology is challenging for the traditional drug discovery pipeline and requires novel drug screening approaches. Notably, in recent years, new methods of oocyst generation, in vitro processing, and continuous three-dimensional cultivation capacities have been developed. This has enabled more physiologically pertinent research assays for inhibitor discovery. In a short time, many great strides have been made in the development of anti- drugs. These are expected to eventually turn into clinical candidates for cryptosporidiosis treatment in the future. This review describes the latest development in biology, genomics, transcriptomics of the parasite, assay development, and new drug discovery.
该物种已被确定为资源有限国家中一种重要的儿童腹泻病原体，尤其是在非常年幼的儿童（0 - 24个月）中。然而，唯一可用的药物（硝唑尼特）疗效有限，且只能在医疗机构中给一岁以上的儿童开处方。许多药物开发项目已开始研究新的治疗途径。该物种独特的生物学特性对传统的药物发现流程构成挑战，需要新颖的药物筛选方法。值得注意的是，近年来，已开发出卵囊生成、体外处理和连续三维培养能力的新方法。这使得能够进行更具生理相关性的抑制剂发现研究测定。在短时间内，抗该物种药物的开发取得了许多重大进展。这些有望最终在未来成为隐孢子虫病治疗的临床候选药物。本综述描述了该物种生物学、基因组学、转录组学、测定方法开发和新药发现的最新进展。
